APOA1 and metabolic dysfunction-associated steatohepatitis: Although these data provide the proof of concept that APOA-I could be extremely helpful in NASH treatment, its use in animal studies or clinical trials has been hampered by the difficulty in producing the recombinant form of this apolipoprotein.